1. Home
  2. RYTM vs DOO Comparison

RYTM vs DOO Comparison

Compare RYTM & DOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$88.26

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo BRP Inc. Common Subordinate Voting Shares

DOO

BRP Inc. Common Subordinate Voting Shares

N/A

Current Price

$58.31

Market Cap

5.6B

ML Signal

N/A

Company Overview

Basic Information
Metric
RYTM
DOO
Founded
2008
1937
Country
United States
Canada
Employees
N/A
17000
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.6B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
RYTM
DOO
Price
$88.26
$58.31
Analyst Decision
Strong Buy
Buy
Analyst Count
14
3
Target Price
$131.14
$85.67
AVG Volume (30 Days)
491.0K
225.1K
Earning Date
05-05-2026
05-28-2026
Dividend Yield
N/A
1.21%
EPS Growth
28.34
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$55.34
$8.48
Revenue Next Year
$86.06
$5.10
P/E Ratio
N/A
$338.95
Revenue Growth
N/A
N/A
52 Week Low
$60.71
$48.83
52 Week High
$122.20
$81.89

Technical Indicators

Market Signals
Indicator
RYTM
DOO
Relative Strength Index (RSI) 49.80 48.34
Support Level $87.19 $52.66
Resistance Level $92.51 $63.86
Average True Range (ATR) 3.56 2.75
MACD -0.24 0.45
Stochastic Oscillator 49.10 51.15

Price Performance

Historical Comparison
RYTM
DOO

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About DOO BRP Inc. Common Subordinate Voting Shares

BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which has largely been divested; Manitou was sold in the third quarter of fiscal 2026, and Telwater remains up for sale. At the end of fiscal 2026, the company sold its products through a network of more than 2,050 independent dealers and 140 distributors in around 110 countries.

Share on Social Networks: